Closed-loop Control of Glucose Levels After Meal Intake in Adults With Type 1 Diabetes
- Conditions
- Type 1 Diabetes
- Registration Number
- NCT01930097
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Brief Summary
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosage based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon.
The objective of this project is to assess whether a dual-hormone closed-loop strategy would alleviate the burden of carbohydrate counting from patients with type 1 diabetes (T1D) without a significant degradation in post-meal glucose control.
Our primary hypothesis is that meal-announcement strategy (pre-meal CHO-independent bolus) is equivalent to meal-and-carbohydrate-announcement strategy (full CHO-matching bolus) during closed-loop regulation of glucose levels in adults with T1D. Our secondary hypothesis is that closed-loop strategy with meal-announcement strategy (pre-meal CHO-independent bolus) or meal-and-carbohydrate-announcement strategy (full CHO-matching bolus) is better than conventional pump treatment in regulation of glucose levels in adults with T1D.
- Detailed Description
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormone: insulin and glucagon.
Each patient will be admitted three times to a clinical research facility. In the meal-and-carbohydrate-announcement visit, patients will eat 3 meals accompanied with a matching insulin bolus (depending on the carbohydrate content of the meal) and glucose levels will be subsequently regulated using dual-hormone closed-loop system. In the meal-announcement visit, patients will eat the 3 same meals but will inject only a partial insulin bolus (not depending on carbohydrate content of the meal) and the remaining needed insulin will be delivered based on glucose sensor excursions as part of closed-loop operation. In the control visit, patients will use conventional pump therapy to regulate glucose levels.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
- Males and females ≥ 18 years of old.
- Clinical diagnosis of type 1 diabetes for at least one year.
- The subject will have been on insulin pump therapy for at least 3 months.
- Last (less than 3 months) HbA1c ≤ 12%.
- Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.
- Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
- Ongoing pregnancy.
- Severe hypoglycemic episode within two weeks of screening.
- Medication likely to affect with the interpretation of the results because of their well known impact on gastric emptying: Motilium®, Prandase®, Victoza®, Byetta® and Symlin®.
- Known or suspected allergy to the trial products, meal contents including nuts, peanuts, dairy products or eggs.
- Unusual nutritional habits (e.g. vegetarians)
- Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
- Failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc).
- Unreliable carbohydrate counting or lack of insulin to carbohydrate ratios
- Problems with venous access
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method The positive incremental area under the curve of postprandial glucose excursions 4 hours after meal intake The positive incremental area under the curve (IAUC, as compared to pre-meal glucose value) of the 4-hr postprandial glucose excursions for the breakfast, lunch and dinner meals.
- Secondary Outcome Measures
Name Time Method Incremental postprandial peak-glucose values 8h00 to 21h00 Mean plasma glucose 8h00 to 21h00 Incremental two hours postprandial glucose 2 hours after meal intake Percentage of time of plasma glucose levels between 4.0 and 10.0 mmol/L 8h00 to 21h00 Percentage of time of plasma glucose levels spent above 10.0 mmol/L 8h00 to 21h00 Percentage of time of plasma glucose levels spent below 4.0 mmol/L 8h00 to 21h00 Total insulin delivery 8h00 to 21h00 Total glucagon delivery 8h00 to 21h00 Standard deviation of glucose levels 8h00 to 21h00 Percentage of time of plasma glucose concentrations below 3.5 mmol/L 8h00 to 21h00 Percentage of time of plasma glucose concentrations above 14 mmol/L 8h00 to 21h00 Mean plasma insulin concentration 8h00 to 21h00 Mean plasma glucagon concentration 8h00 to 21h00 Number of patients experiencing hypoglycemia requiring oral treatment 8h00 to 21h00 Incremental area under the curve of the 4-hr postprandial glucose excursions but the reference glucose is set to 5.0 mmol/L if premeal glucose is less than 5.0 mmol/L. 4 hours after meal intake
Trial Locations
- Locations (1)
Institut de recherches cliniques de Montréal
🇨🇦Montreal, Quebec, Canada
Institut de recherches cliniques de Montréal🇨🇦Montreal, Quebec, Canada